2019
DOI: 10.7759/cureus.6394
|View full text |Cite
|
Sign up to set email alerts
|

A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases

Abstract: Purpose/Objective Published preclinical and phase I clinical trial data suggest that fractionated lesional radiotherapy with 60 Gy in 10 fractions can serve as an alternative approach to single fraction radiosurgical boost for brain oligometastases. Methods and Materials A phase II clinical trial (NCT01543542) of a total of 60 Gy in 10 fractions of lesional (one to three) radiotherapy (given simultaneously with whole-brain helical tomotherapy with 30 Gy in 10 fractions) was conducted at five institutions. We h… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 28 publications
0
3
0
Order By: Relevance
“…One to three brain metastases received 60-Gy WBI in 10 fractions simultaneously with 30-Gy WBI in 10 fractions at five institutions. Median OS was 5.4 months, and 6-month actuarial estimates of intracranial control (ICC) was 78%, demonstrating non-inferiority to the RTOG 9508 historical controls (OS: p = 0.09; ICC = 0.31) [12].…”
Section: Discussionmentioning
confidence: 91%
“…One to three brain metastases received 60-Gy WBI in 10 fractions simultaneously with 30-Gy WBI in 10 fractions at five institutions. Median OS was 5.4 months, and 6-month actuarial estimates of intracranial control (ICC) was 78%, demonstrating non-inferiority to the RTOG 9508 historical controls (OS: p = 0.09; ICC = 0.31) [12].…”
Section: Discussionmentioning
confidence: 91%
“…WBI can cause severe neurotoxicity. The current trend is to do SRS or HSRT whenever possible for cancer patients who had limited number of brain metastases due to equivalent OS with reduced toxicity most notably involving neurocognition [4][5][6][7][8][11][12][13][14][15][16][17][18]. However, even though well tolerated, SRS does have side effects including most concerning radionecrosis (low rate) [14].…”
Section: Discussionmentioning
confidence: 99%
“…The current trend is to use SRS or HSRT whenever possible for patients with cancer who have a limited number of brain metastases due to equivalent OS with reduced toxicity, most notably involving neurocognition. 4 , 5 , 6 , 7 , 8 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 However, even though well tolerated, SRS does have adverse effects, including radionecrosis (low rate). 14 There are questions as to whether current low radionecrosis rates apply to metastatic patients who are living longer owing to improvements in systemic therapy, because in the past these patients would have passed away before developing late neurotoxicity.…”
Section: Discussionmentioning
confidence: 99%